Trial Profile
A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Imatinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 22 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 20 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.